Responders vs clinical response: A critical analysis of data from linaclotide phase 3 clinical trials in IBS-C

Neurogastroenterology and Motility

Volumn 26, Issue 3, 2014, Pages 326-333

  Lacy, B E ^a   Lembo, A J ^b   Macdougall, J E ^c   Shiff, S J ^d   Kurtz, C B ^c   Currie, M G ^c   Johnston, J M ^c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Ironwood Pharmaceuticals   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Abdominal pain; Clinical response; Complete spontaneous bowel movement; Guanylate cyclase type C receptor; IBS C

Indexed keywords

ABDOMINAL PAIN; CLINICAL RESPONSE; COMPLETE SPONTANEOUS BOWEL MOVEMENT; GUANYLATE CYCLASE TYPE-C RECEPTOR; IBS-C;

ABDOMINAL PAIN; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894244905     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12264     Document Type: Article

References (19)

1. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104(Suppl. 1): S1-35.
2. Akehurst RL, Brazier JE, Mathers N, O'Keefe C, Kaltenthaler E, Morgan A, Platts M, Walters SJ. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. PharmacoEconomics 2002; 20: 455-62.
3. Dibonaventura M, Sun SX, Bolge SC, Wagner JS, Mody R. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin 2011; 27: 2213-22.
4. Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, Frech F, Ofman JJ. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003; 98: 600-7.
5. Hillilä MT, Färkkilä NJ, Färkkilä MA. Societal costs for irritable bowel syndrome-a population based study. Scand J Gastroenterol 2010; 45: 582-91.
6. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
7. Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 1910-5.
8. Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010; 86: 760-5.
9. Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Kurtz CB et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007; 133: 761-8.
10. Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Mahajan-Miklos S, Pierce CM et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010; 649: 328-35.
11. Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, Fioramonti J, Cohen M et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010; 22: 312-22.
12. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-25.
13. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702-12.
14. U.S.Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Irritable Bowel Syndrome - Clinical Evaluation of Drugs for Treatment. 2012. Available at: www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf. (accessed December 2013).
15. Macdougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, Shiff SJ, Shi K et al. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil 2013; 25: 481-6.
16. Uryniak T, Chan ISF, Fedorov VV, Jiang Q, Oppenheimer L, Snapinn SM, Teng C-H, Zhang J. Responder analyses- A PhRMA position paper. Stat Biopharm Res 2011; 3: 476-87.
17. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56: 395-407.
18. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 163-9.
19. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-15.